IceCure Medical Ltd. (NASDAQ:ICCM) Receives $62.70 Average PT from Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have earned a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $62.70.

Several equities research analysts recently issued reports on ICCM shares. Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st. Maxim Group decreased their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Finally, Alliance Global Partners started coverage on shares of IceCure Medical in a report on Monday, May 4th. They set a “buy” rating for the company.

Hedge Funds Weigh In On IceCure Medical

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of IceCure Medical during the fourth quarter valued at about $67,000. Concurrent Investment Advisors LLC acquired a new position in shares of IceCure Medical in the fourth quarter valued at approximately $48,000. Finally, Virtu Financial LLC acquired a new position in shares of IceCure Medical in the fourth quarter valued at approximately $39,000. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Stock Down 8.8%

NASDAQ:ICCM opened at $3.33 on Friday. IceCure Medical has a twelve month low of $2.12 and a twelve month high of $42.00. The stock’s 50-day simple moving average is $5.18 and its 200 day simple moving average is $11.96. The firm has a market capitalization of $11.42 million, a PE ratio of -0.46 and a beta of 0.43.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The business had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. On average, analysts anticipate that IceCure Medical will post -3.51 EPS for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.